Acutaas Chemicals has promoted Anurag Shukla to the role of General Manager Operations & Unit Head – Ankleshwar, effective July 2, 2026. The company's Nomination and Remuneration Committee approved the designation of Shukla as a Senior Management Personnel (SMP) during a meeting held on the same date. This strategic elevation aims to strengthen the leadership overseeing the company's manufacturing facility in Ankleshwar.

Shukla has been associated with the company since September 1, 2021, joining as a Senior Manager before serving as Assistant General Manager – Operations. In his new capacity, he will be responsible for overseeing the overall operations of the Ankleshwar manufacturing facility. He brings over 21 years of experience in pharmaceutical API and intermediates manufacturing, plant operations, and regulatory compliances.

The appointment was intimated to the stock exchanges pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The disclosure was also read with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026.

Profile of the Appointee

Shukla holds a Master of Science in Organic Chemistry. His expertise includes setting up manufacturing facilities, leading regulatory audits by global agencies, driving operational excellence, and cost optimisation. Prior to joining Acutaas Chemicals, he held leadership positions at Alembic Pharmaceuticals Limited, IPCA Laboratories Limited, Dishman Pharmaceuticals & Chemicals Limited, Kalki Healthcare Private Limited, and Avitech Nutrition Private Limited.

Key Appointment Details

Acutaas Chemicals Limited has released its corporate presentation for investor conferences scheduled between May 27 and June 16, 2026. The disclosure, filed on May 16, 2026, outlines the company's financial performance for FY26 and its strategic growth initiatives. Company officials will attend one-on-one and group meetings across Mumbai, Hong Kong, Singapore, and London to discuss these developments.

Financial Performance

The company reported a Profit After Tax (PAT) of ₹ 3,564 Mn for FY26, a significant increase from ₹ 1,604 Mn in FY25. The PAT margin for FY26 stood at 26.6%. Revenue from operations for FY26 rose to ₹ 13,394 Mn, compared to ₹ 10,069 Mn in the previous fiscal year. EBITDA for FY26 was ₹ 4,804 Mn, with an EBITDA margin of 35.9%.

Business Overview

Acutaas Chemicals operates across four primary segments: Pharmaceutical Intermediates, Semiconductor Chemicals, Battery Chemicals, and Commodity Chemicals. The Pharmaceutical Intermediates segment contributed 87.7% to the total revenue, generating ₹ 11,741 Mn in FY26. The company holds a 50-90% global market share in key intermediates and is the only manufacturer in India for photoresist chemicals.

Growth Strategy

The company is investing ₹ 1000+ Cr. for sustainable future growth from FY23 to FY30. This includes significant capital expenditure in Pharma, Battery, and Semiconductor segments. The Pharma segment has completed a 3x capacity expansion at the Ankleshwar site. The Battery Chemicals segment is ongoing with a total capex of ~ ₹ 220 Cr., while the Semiconductor segment is investing ~ ₹ 200 Cr. in its joint venture, Indichem, in South Korea.

Investor Conference Schedule

The company has outlined participation in four distinct conference events:

Acutaas Chemicals clarified that no unpublished price-sensitive information is intended to be discussed during these conferences. The corporate presentation is available on the company's website.